These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18519814)

  • 1. Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.
    Lin W; Voskens CJ; Zhang X; Schindler DG; Wood A; Burch E; Wei Y; Chen L; Tian G; Tamada K; Wang LX; Schulze DH; Mann D; Strome SE
    Blood; 2008 Aug; 112(3):699-707. PubMed ID: 18519814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK cell expression of Tim-3: First impressions matter.
    So EC; Khaladj-Ghom A; Ji Y; Amin J; Song Y; Burch E; Zhou H; Sun H; Chen S; Bentzen S; Hertzano R; Zhang X; Strome SE
    Immunobiology; 2019 May; 224(3):362-370. PubMed ID: 30876792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.
    Sallin MA; Zhang X; So EC; Burch E; Cai L; Lin W; Chapoval AI; Strome SE
    Cancer Immunol Immunother; 2014 Sep; 63(9):947-58. PubMed ID: 24927849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
    Kohrt HE; Houot R; Goldstein MJ; Weiskopf K; Alizadeh AA; Brody J; Müller A; Pachynski R; Czerwinski D; Coutre S; Chao MP; Chen L; Tedder TF; Levy R
    Blood; 2011 Feb; 117(8):2423-32. PubMed ID: 21193697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody.
    Hong JP; McCarthy MK; Davenport BJ; Morrison TE; Diamond MS
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
    Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
    Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.
    Misumi T; Tanabe K; Fujikuni N; Ohdan H
    PLoS One; 2018; 13(10):e0204880. PubMed ID: 30321186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
    Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The low affinity 40,000 Fc gamma receptor and the transferrin receptor can be alternative or simultaneous target structures on cells sensitive for natural killing.
    Perl A; Looney RJ; Ryan DH; Abraham GN
    J Immunol; 1986 Jun; 136(12):4714-20. PubMed ID: 3011902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity.
    Wilcox RA; Tamada K; Strome SE; Chen L
    J Immunol; 2002 Oct; 169(8):4230-6. PubMed ID: 12370353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.
    Baessler T; Charton JE; Schmiedel BJ; Grünebach F; Krusch M; Wacker A; Rammensee HG; Salih HR
    Blood; 2010 Apr; 115(15):3058-69. PubMed ID: 20008791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
    Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
    ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Fc mu receptor on human natural killer cells. Interaction with its physiologic ligand, human normal IgM, specificity of binding, and functional effects.
    Pricop L; Rabinowich H; Morel PA; Sulica A; Whiteside TL; Herberman RB
    J Immunol; 1993 Sep; 151(6):3018-29. PubMed ID: 7690792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses.
    Vinay DS; Choi BK; Bae JS; Kim WY; Gebhardt BM; Kwon BS
    J Immunol; 2004 Sep; 173(6):4218-29. PubMed ID: 15356173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
    Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
    J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression.
    Masu T; Atsukawa M; Nakatsuka K; Shimizu M; Miura D; Arai T; Harimoto H; Kondo C; Kaneko K; Futagami S; Kawamoto C; Takahashi H; Iwakiri K
    PLoS One; 2018; 13(12):e0200664. PubMed ID: 30596643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.